Picture of Theralink Technologies logo

OBMP — Theralink Technologies Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeLarge CapNeutral

Momentum

Relative Strength (%)
1m-21%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-82%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 202130th Sep 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Theralink Technologies EPS forecast chart

Profile Summary

Theralink Technologies, Inc., formerly OncBioMune Pharmaceuticals, Inc., is a commercial-stage precision medicine and molecular data-generating company. The Company focuses on the development and commercialization of a series of data-generating assays that provide actionable information for physicians and patients, as well as biopharmaceutical companies, in the areas of oncology. The Company is advancing its technology in the field of phosphoproteomic research. The Theralink assay uses Reverse Phase Protein Array (RPPA) technology to measure the abundance and activation of cell surface receptor proteins and their downstream signaling pathways. The Theralink platform generates an accurate and comprehensive portrait of protein pathway activation in diseased cells from each patient, and thereby determines which individuals be better responders to certain targeted molecular therapies. The platform enables the quantitative measurement of the level of activation.

Directors

Last Annual
September 30th, 2020
Last Interim
June 30th, 2021
Incorporated
March 18th, 2005
Public Since
February 8th, 2002
No. of Employees
3
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
5,555,474,594

OBMP Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email